With the launch of Sitagliptin Impurity A, the inventory of Indian Pharmacopoeial Reference Standards has reached the 1000 mark.

The Indian Pharmacopoeia Commission (IPC) has become the third pharmacopoeia commission in the world to have more than 1000 pharmacopoeial reference standards in its inventory.

Sitagliptin is a dipeptidyl peptidase-4 inhibitor and is used to improve glycemic control in patients with type 2 diabetes.

During the 50th Scientific Body meeting of the Indian Pharmacopoeia Commission on September 28, 2022, the 1000th IP Reference Standard- Sitagliptin Impurity A was launched by members of the Scientific Body.

Click for more on IPC

Sitagliptin is among 15 impurities launched by IPC recently.

The other impurities are:

- Amiodarone Impurity A,
- Amiodarone Impurity B,
- Amlodipine Impurity D,
- Cefradine, Cephraddine,
- Diazepam Impurity B,
- Econazole Nitrate,

- Fenbendazole Impurity B,
- Fluconazole Impurity C,
- Indapamide Impurity A,
- Norfloxacin Impurity E,
- Quetiapine Impurity A,
- Teneligliptin Impurity C,
- 6-chloro-3-hydroxyamide (Chlor Homolog impurity).

IPC launched the first Reference Standard of the anti-diabetic drug, Pioglitazone, in 2010.

Later, the Indian Pharmacopoeia 2014 contained separate monographs for anti-diabetic drugs, metformin tablets, and metformin prolonged-release tablets.In August this year, IPC added five new Indian Pharmacopoeial Reference Standards and seven new impurity reference substances to Indian Pharmacopoeia 2022.

The list of impurity reference substances contained:

- Clobazam impurity A,
- Levocetirizine amide,
- Lumefantrine-related compound A,
- Quetiapine impurity I,
- Tamoxifen citrate impurity standard,
- Tinidazole impurity B,
- Trimethoprim impurity B.

On the other hand, the list of Indian Pharmacopoeial Reference Standards included disopyramide phosphate, dolutegravir sodium, estradiol hemihydrate, propofol, and tenofovir alafenamide fumarate.Impurity standards are used to perform the system suitability and qualitative and quantitative parameters for compliance with the Indian Pharmacopoeia monograph.The IP is a legally recognized book of standards for drugs and their formulations in India.

The standards of identity, purity, and strength prescribed in IP are to ensure the quality of the medicine.

The mandate of the commission is to perform, inter-alia, functions such as revision and publication of the Indian Pharmacopoeia and National Formulary of India on a regular basis besides providing IP reference substances and training to the stakeholders on pharmacopoeial issues.

Buying Indian Pharmacopoeial Reference Standard is a social and legal responsibility of the industry, stated the commission.

Other articles on IPC

IPC adds 7 new Veterinary Monographs, 8 new Chemical Monographs to IP 2022

IPC alerts about Cefoperazone induced coagulopathy

IPC clarifies: General Chapter on ‘Uniformity of Dosage Units’ in IP 2022 not mandatory

IPC adds 5 new IP Reference Standards & 7 new Impurities to IP 2022

IPC releases revised draft general chapters on microbiology in IP

IPC flags safety alert against immunosuppressive drug Tacrolimus

IPC releases IP 2022, 92 new monograph, 27 APIs added: Read details

IPC flags safety alert against Blood Pressure drug, Losartan

IPC to include Dissolution Test in prolonged-release formulations in IP

IPC to develop & revise IP general chapters, Monographs

IPC flags safety alert against most common Drug Ibuprofen – NSAID

Pharma Industry urges IPC to defer implementation of monograph of Ferrous Ascorbate IP 2018...

Latest Circulars: (IPC) Indian Pharmacopoeia Commission

Latest Notifications regarding Pharmaceuticals

Latest on National Formulary of India (NFI)

Safety alerts issued by IPC

NDPS: Inter-state Pharmaceutical drug racket busted

USFDA issues 2 observations on Form 483 to Zydus Lifesciences

DCGI panel recommends ban on these Fixed dose combination drugs

Bar codes could come soon to stop the threat of sub-standard drugs

Govt notifies RDTL Chandigarh as Central Medical Devices Testing Laboratory

Drug recall: Acyclovir Sodium Injection recalled due to this reason

Changing the Regulations for Class A Medical Devices and its Impact

Govt plan to ban Codeine based cough syrups opposed by Pharma companies

Pharmacists – The Doctors behind the screens

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/10/03/ipc-launches-1000th-ip-reference-standard/